Earnings week ahead: AMD, PLTR, PFE, DIS, O, ET, SHOP, GILD, MCD, CAT, VTRS, BP, UBER, CGC, and more

As Wall Street embarks on the first full week of August, the earnings wave continues with another stacked week of reports spanning tech, energy, healthcare, consumer, and industrial sectors offering a comprehensive read on corporate health, capital allocation, and demand signals across the economy.

Tech & Software: Investors will be tuned in for results from Advanced Micro Devices (NASDAQ:AMD), Palantir (NASDAQ:PLTR), Arista Networks (NYSE:ANET), Fortinet (NASDAQ:FTNT), Unity Software (NYSE:U), Super Micro Computer (NASDAQ:SMCI), Datadog (NASDAQ:DDOG), Snap (NYSE:SNAP), Pinterest (NYSE:PINS), Twilio (NYSE:TWLO), The Trade Desk (NASDAQ:TTD), Block (XYZ), and Upstart (NASDAQ:UPST) as AI, security, and digital ads remain in focus.

Energy & Materials: Heavyweights Occidental Petroleum (NYSE:OXY), ConocoPhillips (NYSE:COP), Devon Energy (NYSE:DVN), Suncor Energy (NYSE:SU), BP (NYSE:BP), Petrobras (NYSE:PBR), Marathon Petroleum (NYSE:MPC), Transocean (NYSE:RIG), MPLX LP (NYSE:MPLX), ONEOK (NYSE:OKE), Energy Transfer (NYSE:ET), and EOG Resources (NYSE:EOG) will provide updates on pricing, production, and macro risk. Also reporting: Archer-Daniels-Midland (NYSE:ADM), Nutrien (NYSE:NTR), Pan American Silver (NYSE:PAAS), and DuPont (NYSE:DD).

Healthcare & Biotech: Key updates expected from Pfizer (NYSE:PFE), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Vertex Pharma (VRTX), Eli Lilly (LLY), Viatris (VTRS), Novo Nordisk (NVO), and Organon (OGN), with a spotlight on drug pipelines and margin trends. Aurora Cannabis (ACB) and Canopy Growth (CGC) also report, adding to the narrative in cannabis healthcare.

Consumer & Travel: Expect insights from McDonald’s (MCD), The Walt Disney Company (NYSE:DIS), Airbnb (ABNB), Shopify (SHOP), Beyond Meat (BYND), and Uber (UBER), all reporting amid shifting consumer spending and travel patterns.

Industrial & REITs: Watch for updates from Caterpillar (CAT), Emerson Electric (EMR), Iron Mountain (IRM), and Simon Property Group (SPG)—alongside business development and REIT names like Realty Income (O), Main Street Capital (MAIN), and Blue Owl Capital (OWL).

Autos & EVs: EV trends will be in focus as Lucid Group (LCID) and Rivian (RIVN) report, with investors watching order flow, production, and cash burn.

Media & Gaming: Digital media and streaming get the spotlight with reports from Warner Bros. Discovery (NASDAQ:WBD) and Virgin Galactic (SPCE), while Take-Two Interactive (TTWO) and DraftKings (DKNG) add depth from the gaming and betting world.

With broad sector participation and macro risks still in play, this week’s earnings reports will be a key test for sentiment and valuation across markets.

Below is a rundown of major earnings reports due in the week of August 4 to August 8:

Monday, August 4

Palantir Technologies (NASDAQ:PLTR)

Palantir Technologies (NASDAQ:PLTR) is set to release its Q2 earnings after the market closes on Monday, with analysts forecasting a nearly 54% jump in EPS and over 38% Y/Y revenue growth.

The Denver-based software firm has seen its stock surge approximately 488% over the past year and more than 100% in 2025 alone. Despite this meteoric rise, both Wall Street analysts and Seeking Alpha’s Quant Rating system maintain a Hold rating, citing valuation concerns.

Piper Sandler recently initiated coverage with an Overweight rating and a $170 price target, calling Palantir a rare “AI secular winner” with potential to scale to a $24B run rate by 2032. Analyst Brent Bracelin points to two key growth engines: the U.S. government segment, expected to surpass $10B by 2030, and the commercial division, projected to top $5B by then. With a current revenue run-rate near $4B and free cash flow margins above 40%, Bracelin acknowledges the upside but advises waiting for a pullback due to the stock’s high valuation and volatility.

In contrast, bearish Seeking Alpha contributor Louis Gerard warns that Palantir’s sky-high valuation leaves little margin for error. He argues that the stock is fueled more by hype than fundamentals, pointing to insider selling, dilution from stock-based compensation, and growing competition in AI and analytics as significant risks. While Palantir’s growth and margins are strong, Gerard views the stock’s current pricing as unjustifiable and maintains a Sell rating.

• Consensus EPS Estimates: $0.14
• Consensus Revenue Estimates: $939.47M
• Earnings Insight: The stock has beaten revenue and EPS expectations in 7 of the past 8 quarters.

Also reporting: Simon Property Group (SPG), MercadoLibre (MELI), Transocean (NYSE:RIG), ONEOK (NYSE:OKE), Vertex Pharmaceuticals (VRTX), BioNTech SE (BNTX), Tanger Factory Outlet (SKT), Williams Companies (WMB), ON Semiconductor (ON), Diamondback Energy (FANG), Tyson Foods (TSN), Contura Energy (CTRA), LTC Properties (LTC), Wayfair (W), and more.

Tuesday, August 5

Advanced Micro Devices (NASDAQ:AMD)

Advanced Micro Devices (NASDAQ:AMD) is set to report its Q2 earnings after the market closes on Tuesday. While analysts anticipate a robust 27% Y/Y revenue increase, profits are expected to decline by 30%, reflecting margin pressures and elevated R&D spending.

The stock has delivered a 22% gain over the past 12 months and surged roughly 46% YTD. Despite this momentum, sentiment remains mixed. Wall Street analysts maintain a Buy rating, whereas Seeking Alpha’s quant rating system recommends a more cautious Hold.

SA contributor Oliver Rodzianko echoes the caution, having closed out his AMD position after a 75% gain in early 2025. He warns that AMD’s valuation appears overstretched in the near term and advises long-term investors to consider trimming exposure, while active traders might take profits ahead of potential volatility.

On the other hand, Seeking Alpha Investing Group Leader Tech Stock Pros maintains a Buy rating, highlighting AMD’s strength in CPU sales over AI as the real near-term driver. With the stock up 126% heading into earnings outpacing Nvidia, investors are debating whether gains will hold. The group points to possible tariff-driven pull-ins and positive tailwinds from Instinet MI350 pricing and a potential pause in China export restrictions. While Q2 may still carry volatility, they view Q3 as the real pivot point for reassessing AMD’s growth trajectory.

• Consensus EPS Estimates: $0.48
• Consensus Revenue Estimates: $7.43B
• Earnings Insight: AMD has surpassed EPS expectations in 7 of the past 8 quarters, and revenue in 100% of those reports.

Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) is slated to report its Q2 earnings before the market opens on Tuesday, with Wall Street expecting modest revenue growth and a decline in earnings per share.

The company recently received EU approval for its updated COVID shot and has begun manufacturing its LP.8.1-adjusted vaccine ahead of the fall season.

While sell-side analysts maintain a Buy rating on the stock, Seeking Alpha’s quant rating remains more cautious with a Hold, reflecting persistent concerns over growth and valuation.

SA Investing Group Leader JR Research also suggests a Hold, pointing to weak healthcare sentiment driven by regulatory overhang, competition from obesity drugs, and underwhelming insurer results. JR highlights that Pfizer’s oncology pipeline must deliver to counteract looming patent expirations and restore market confidence. Despite its 7% dividend yield and seemingly undervalued shares, he notes that near-term catalysts are lacking.

In contrast, SA contributor Yiannis Zourmpanos rates the stock a Buy, emphasizing Pfizer’s $7.7B cost-savings initiative, which is helping to stabilize margins and EPS despite post-COVID revenue normalization. With core revenue growing 12% excluding COVID-related income and strong performance in oncology, vaccines, and internal medicine, he believes Pfizer’s aggressive R&D and acquisition strategy could counter upcoming losses from expiring patents. Trading at just ~9x forward earnings well below its historical average, Zourmpanos argues Pfizer offers long-term upside and significant re-rating potential.

• Consensus EPS Estimates: $0.57
• Consensus Revenue Estimates: $13.53B
• Earnings Insight: Pfizer has beaten EPS estimates in a straight 8 quarters, exceeding revenue estimates in 4 of those reports.

Also reporting: BP (NYSE:BP), Caterpillar (CAT), Lucid Group (LCID), Organon (OGN), Amgen (NASDAQ:AMGN), Snap (NYSE:SNAP), Skyworks Solutions (SWKS), Duke Energy (DUK), DuPont (NYSE:DD), Upstart Holdings (NASDAQ:UPST), Lemonade (LMND), Devon Energy (NYSE:DVN), Digital Turbine (APPS), Archer-Daniels-Midland (NYSE:ADM), Rivian Automotive (RIVN), MPLX LP (NYSE:MPLX), Cummins (CMI), Marathon Petroleum (NYSE:MPC), Arista Networks (NYSE:ANET), Opendoor Technologies (OPEN), AFLAC (AFL), Mosaic (MOS), NNN REIT (NNN), Marriott International (MAR), Uniti Group (UNIT), Yum! Brands (YUM), Clover Health (CLOV), Match Group (MTCH), and more.

Wednesday, August 6

The Walt Disney Company (NYSE:DIS)

Disney (DIS) is set to report its FQ3 earnings before the market opens on Wednesday.

The stock has gained around 7% YTD, and while Wall Street analysts maintain a Buy rating, Seeking Alpha’s Quant Rating has been less consistent, fluctuating from Hold to Strong Buy in mid-July before reverting to Hold just days before earnings.

SA Investing Group Leader Daniel Jones holds a highly bullish outlook on Disney, emphasizing the often-overlooked upside potential of its Sports segment, particularly ESPN. He argues that ESPN’s evolving business model, including the anticipated direct-to-consumer streaming app with flexible pricing and bundling options, could generate as much as $3B in annual revenue. Jones sees this as a key driver of long-term growth. He also points to recent improvements in Disney’s financials, including rising revenue and operating income in 2025, fueled by effective cost controls and gains in advertising and subscriptions. Despite industry-wide challenges like cord-cutting, he believes Disney’s dominant sports position and innovative streaming strategies offer strong potential for long-term shareholder value.

• Consensus EPS Estimates: $1.45
• Consensus Revenue Estimates: $23.76B
• Earnings Insight: Disney has topped EPS expectations straight 8 quarters, missing revenue expectations in 50% of those reports.

Shopify (SHOP)

Shopify (SHOP) is scheduled to report its Q2 earnings before the market opens on Wednesday, with analysts forecasting a solid quarter profit to grow ~10% Y/Y, while revenue is projected to increase by 25%.

Seeking Alpha’s Quant Rating system remains cautious with a Hold rating, citing valuation concerns. In contrast, Wall Street analysts maintain a Buy consensus, supported by the stock’s nearly 100% gain over the past year.

SA author Pau Galindo Ortigosa rates SHOP a Buy, pointing to continued 20%+ annual revenue growth, robust international expansion, and a capital-light SaaS model that drives consistent free cash flow and improving margins. With a strong balance sheet of $5.5B in cash and low debt, Shopify is positioned to scale its high-margin services globally. Risks include macro pressure and growing competition, but the long-term growth story remains intact.

Meanwhile, Lighting Rock Research reiterates a Sell rating, citing overvaluation. While acknowledging Shopify’s operational execution and global fintech expansion, they argue the stock trades well above its fair value estimate of $96 per share. Trade-related uncertainties and cross-border e-commerce risks could also weigh on near-term performance, justifying a more cautious outlook.

• Consensus EPS Estimates: $0.29
• Consensus Revenue Estimates: $2.55B
• Earnings Insight: Shopify has beaten EPS estimates in 2 of the past 8 quarters and revenue expectation in consecutive all of them.

Also reporting: Realty Income (O), Energy Transfer LP (NYSE:ET), Aurora Cannabis (ACB), McDonalds (MCD), Airbnb (ABNB), Iron Mountain (IRM), Occidental Petroleum (NYSE:OXY), Uber Technologies (UBER), Virgin Galactic Holdings (SPCE), DraftKings (DKNG), Unity (NYSE:U), Beyond Meat (BYND), Novavax (NVAX), Fastly (FSLY), Corteva (CTVA), Nutrien (NYSE:NTR), Brookfield Asset Management (BAM), Zillow (Z), Emerson Electric (EMR), American International Group (AIG), Fortinet (NASDAQ:FTNT), Apache (APA), Novo Nordisk A/S (NVO), Federal Realty Investment Trust (FRT), MannKind (MNKD), Chimera Investment (CIM), Sarepta Therapeutics (SRPT), Metlife (MET), Exact Sciences (EXAS), Lyft (LYFT), Curaleaf Holdings (OTCPK:CURLF), Pan American Silver (NYSE:PAAS), Sunrun (RUN), and more.

Thursday, August 7

Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) is set to report its Q2 earnings after the market closes on Thursday.

The stock has gained 22% YTD and nearly 48% over the past 12 months, reflecting growing investor confidence.

The optimism was further reinforced when Needham upgraded GILD to Buy, citing strong early momentum for its newly approved HIV prevention drug Yeztugo (lenacapavir). The firm expects Yeztugo to capture ~38% of the PrEP market by 2030, based on survey data, which they believe is not fully reflected in current consensus models. Their price target is $133 per share.

The U.S. FDA approved Yeztugo in June for HIV pre-exposure prophylaxis in adults and adolescents, marking a major step forward in Gilead’s innovation pipeline.

Reflecting this potential, Seeking Alpha’s Quant Rating system recently upgraded GILD to Strong Buy, while Wall Street analysts maintain a Buy rating.

However, sentiment is not unanimously bullish. Envision Research, an SA Investing Group Leader, downgraded GILD to Sell, arguing that Merck (NYSE:MRK) is a stronger dividend play with superior valuation and dividend growth metrics. While GILD shows solid inventory management and cash flow, it faces ongoing headwinds from aging HCV/HIV franchises and long-term demand concerns.

• Consensus EPS Estimates: $1.96
• Consensus Revenue Estimates: $6.96B
• Earnings Insight: The company has beaten revenue expectations in 7 of the past 8 quarters and EPS expectations in 6 of those reports.

Also reporting: Viatris (VTRS), Twilio (NYSE:TWLO), ConocoPhillips (NYSE:COP), Trade Desk (NASDAQ:TTD), Pinterest (NYSE:PINS), Main Street Capital Holdings (MAIN), Eli Lilly (LLY), Cronos Group (CRON), Wheaton Precious Metals (WPM), Peloton Interactive (PTON), Datadog (NASDAQ:DDOG), Skillz (SKLZ), Blink Charging (BLNK), Wynn Resorts (WYNN), SolarEdge Technologies (SEDG), Warner Bros. Discovery (NASDAQ:WBD), Atlassian Corporation (TEAM), Dropbox (DBX), Cheniere Energy (LNG), PENN Entertainment (PENN), Consolidated Edison (ED), Starwood Property Trust (STWD), Clean Energy Fuels (CLNE), Sony Group (SONY), Take-Two Interactive Software (TTWO), Himax Technologies (HIMX), MP Materials (MP), Intellia Therapeutics (NTLA), Pembina Pipeline (PBA), Appian (APPN), BCE (BCE), Sandstorm Gold (SAND), Becton, Dickinson (BDX), Canadian Natural Resources (CNQ), Elanco Animal Health (ELAN), Expedia (EXPE), StoneCo (STNE), HASI (HASI), PacBio (PACB), Toyota Motor (TM), and more.

Friday, August 8

Canopy Growth (CGC)

Canopy Growth (CGC) is scheduled to report its FQ1 earnings before the market opens on Friday, with analysts projecting an ~87% Y/Y improvement in profits.

The update comes on the heels of a leadership shakeup: last month, the company appointed Tom Stewart as interim CFO, replacing Judy Hong. Stewart, who joined Canopy in 2019 as Chief Accounting Officer, assumes the role amid persistent volatility in the cannabis sector.

CGC shares have plunged more than 86% over the past 12 months, underscoring investor concerns about long-term viability and sector headwinds.

Reflecting those worries, Seeking Alpha’s Quant Rating system downgraded CGC to Strong Sell in mid-July, flagging high risk, decelerating momentum, and negative EPS revisions relative to other healthcare stocks. Wall Street analysts, meanwhile, have adopted a Hold rating.

SA contributor Alan Sumler also rates CGC as a Hold, noting that while near-term pain persists, there’s potential for operational improvements and a rebound in FY2026.

• Consensus EPS Estimates: -$0.14
• Consensus Revenue Estimates: $47.10M
• Earnings Insight: The company has beaten revenue expectations in 4 of the past 8 quarters, and EPS expectations only once in that time span.

Also reporting: EOG Resources (NYSE:EOG), fuboTV (FUBO), Under Armour (UAA) (UA), Plains All American Pipeline, L.P. (PAA), Algonquin Power & Utilities (AQN), Wendy’s International (WEN), Gray Television (GTN), Calumet Specialty Products Partners, L.P. (CLMT), and more.